Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.52 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804623 | 0.86 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL431291 | 0.86 | HMGCR (0.55) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL14403869 | 0.85 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2341001 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL4620964 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL2347371 | 0.85 | HMGCR (0.54) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL28860507 | 0.84 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL29482554 | 0.84 | HMGCR (0.58) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL28494229 | 0.84 | HMGCR (0.56) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 | |
| SCHEMBL13538 | 0.84 | HMGCR (0.61) | HMGCRALDH1A1CYP3A4PDE6DNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| CN-101084197-A | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD (GB) | 2007-12-05 | — | — | CN | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | RATIOPHARM GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-8034932-B2 | Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin | ASTRAZENECA UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | disclosed |
| CN-101084197-A | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD (GB) | 2007-12-05 | — | — | CN | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295005-A1 | PROCESS FOR PREPARING PYRIMIDINE DERIVATIVES | HMGCR, DPYD, FDPS | HMGCR 1/4885ALDH1A1 1104/4885CYP3A4 87/4885 |
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | HMGCR 306/4885ALDH1A1 410/4885CYP3A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.